Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Implementation and evaluation of a gravimetric i.v. workflow software system in an oncology ambulatory care pharmacy.

Reece KM, Lozano MA, Roux R, Spivey SM.

Am J Health Syst Pharm. 2016 Feb 1;73(3):165-73. doi: 10.2146/ajhp150169.

PMID:
26796911
2.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.

3.

Visualization of subunit interactions and ternary complexes of protein phosphatase 2A in mammalian cells.

Mo ST, Chiang SJ, Lai TY, Cheng YL, Chung CE, Kuo SC, Reece KM, Chen YC, Chang NS, Wadzinski BE, Chiang CW.

PLoS One. 2014 Dec 23;9(12):e116074. doi: 10.1371/journal.pone.0116074. eCollection 2014.

4.

Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II).

Jayatunga MK, Thompson S, McKee TC, Chan MC, Reece KM, Hardy AP, Sekirnik R, Seden PT, Cook KM, McMahon JB, Figg WD, Schofield CJ, Hamilton AD.

Eur J Med Chem. 2015 Apr 13;94:509-16. doi: 10.1016/j.ejmech.2014.06.006. Epub 2014 Jun 27.

5.

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.

Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD.

Mol Cancer. 2014 Apr 28;13:91. doi: 10.1186/1476-4598-13-91.

6.

Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?

Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.

BMJ Open. 2013 Jan 3;3(1). pii: e002030. doi: 10.1136/bmjopen-2012-002030.

7.

Contribution of the OATP1B subfamily to cancer biology and treatment.

Sissung TM, Reece KM, Spencer S, Figg WD.

Clin Pharmacol Ther. 2012 Nov;92(5):658-60. doi: 10.1038/clpt.2012.127. Epub 2012 Sep 26. Review. No abstract available.

8.

A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting.

Reece KM, Figg WD.

Cancer Biol Ther. 2010 Apr 15;9(8):583-4. No abstract available.

PMID:
20720457
9.

The Balpha and Bdelta regulatory subunits of PP2A are necessary for assembly of the CaMKIV.PP2A signaling complex.

Reece KM, Mazalouskas MD, Wadzinski BE.

Biochem Biophys Res Commun. 2009 Sep 4;386(4):582-7. doi: 10.1016/j.bbrc.2009.06.062. Epub 2009 Jun 16.

Supplemental Content

Loading ...
Support Center